TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34500245

Group type: COMPARATOR
Intervention: Traditional PNF
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Social media inspired gamified PNF
Number of subjects: 223

Group type: COMPARATOR
Intervention: Gamified only PNF
Number of subjects: 223
Study: 32476140

Group type: COMPARATOR
Intervention: Lower fat diet
Number of subjects: 57079
Study: 36200921

Group type: EXPERIMENTAL
Intervention: HA-filler serum (applied starting 24 hours after BoNTA injection, then twice daily for 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BoNTA (control group)
Number of subjects: 0
Study: 32842336

Group type: EXPERIMENTAL
Intervention: LenSx
Number of subjects: 86

Group type: COMPARATOR
Intervention: LenSAR
Number of subjects: 86
Study: 33793285

Group type: EXPERIMENTAL
Intervention: Baseline psychological distress
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Inadequate income
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: At least one ADL deficit
Number of subjects: 513
Study: 34343687

Group type: EXPERIMENTAL
Intervention: DCB + EPD
Number of subjects: 95

Group type: COMPARATOR
Intervention: BMS without EPD
Number of subjects: 95
Study: 32098575

Group type: EXPERIMENTAL
Intervention: Death over Dinner
Number of subjects: 109

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 109
Study: 34857525

Group type: COMPARATOR
Intervention: Danazol 800 mg daily in two divided doses for adults or 2 mg/kg/day for children, escalating to 4 mg/kg/day if no side effects are encountered, for a total of 12 months for adults and 6 months for children.
Number of subjects: 0
Study: 35504508

Group type: EXPERIMENTAL
Intervention: HeartMate 3 (HM3) implantation
Number of subjects: 1958
Study: 33293274

Group type: EXPERIMENTAL
Intervention: LDL-C concentrations <1.8 mmol/L (<70 mg/dL; 1st-5th centiles)
Number of subjects: 108243

Group type: EXPERIMENTAL
Intervention: LDL-C concentrations >4.8 mmol/L (>189 mg/dL; 96th-100th centiles)
Number of subjects: 108243

Group type: COMPARATOR
Intervention: LDL-C concentration of 3.6 mmol/L (140 mg/dL)
Number of subjects: 108243

Group type: COMPARATOR
Intervention: LDL-C concentration of 2.3 mmol/L (89 mg/dL)
Number of subjects: 108243

Group type: EXPERIMENTAL
Intervention: Any increase in LDL-C levels
Number of subjects: 108243
Study: 32905611

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA) - bolus dose of 10 mg kg−1 followed by 8 hours continuous infusion of 3 mg kg−1 h−1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32916606

Group type: EXPERIMENTAL
Intervention: Lower female hs‐cTn thresholds implemented in hospitals
Number of subjects: 30

Group type: COMPARATOR
Intervention: Overall hs‐cTn thresholds for men
Number of subjects: 30
Study: 32245305

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional oxygen therapy (COT)
Number of subjects: 40
Study: 35149538

Group type: EXPERIMENTAL
Intervention: Alpelisib plus Olaparib
Number of subjects: 17
Study: 33180007

Group type: EXPERIMENTAL
Intervention: Acute beetroot juice supplementation (70 mL, 6.4 mmol NO3‐)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (0.005 mmol NO3‐)
Number of subjects: 9
Study: 33998555

Group type: EXPERIMENTAL
Intervention: Morning Walk®
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group)
Number of subjects: 36
Study: 35778796

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage combined with vacuum sealing drainage
Number of subjects: 102

Group type: COMPARATOR
Intervention: Health education and functional training (Control)
Number of subjects: 102
Study: 33949017

Group type: EXPERIMENTAL
Intervention: 12-lead Holter recordings
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resting ECGs
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous recordings
Number of subjects: 40
Study: 34097862

Group type: EXPERIMENTAL
Intervention: Heartfulness meditation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 32808409

Group type: EXPERIMENTAL
Intervention: Active soft tissue therapy (stretching exercise + active soft tissue therapy)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Graston technique (stretching exercise + Graston technique)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (stretching exercise only)
Number of subjects: 45
Study: 33174199

Group type: EXPERIMENTAL
Intervention: 14 cm head elevation (high group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Conventional 7 cm head elevation (control group)
Number of subjects: 110
Study: 34653651

Group type: COMPARATOR
Intervention: Infographic versions of the trial's website landing page (Experiment 1)
Number of subjects: 2979

Group type: COMPARATOR
Intervention: Video versions of the trial's website landing page (Experiment 2)
Number of subjects: 2979
Study: 33478718

Group type: EXPERIMENTAL
Intervention: Videos of newborn photographs with classical music (Group A)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Video of the newborn photograph album (Group B)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Introductory film of Turkey (Group C)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Only classical music (Group D)
Number of subjects: 273

Group type: COMPARATOR
Intervention: Routine hospital care (Group E)
Number of subjects: 273
Study: 35086112

Group type: EXPERIMENTAL
Intervention: 0.35% levobupivacaine (7 mL/h for 48 hours)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 70
Study: 34601736

Group type: EXPERIMENTAL
Intervention: IV ibuprofen 800 mg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74

Group type: COMPARATOR
Intervention: IV ibuprofen 800 mg and Placebo
Number of subjects: 74
Study: 32039811

Group type: EXPERIMENTAL
Intervention: Let's Talk About Smoking
Number of subjects: 162

Group type: COMPARATOR
Intervention: NCI Education
Number of subjects: 162
Study: 36100943

Group type: EXPERIMENTAL
Intervention: Virtual reality therapy (7 sessions within 12 weeks)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Supportive counselling (7 sessions within 12 weeks)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Virtual reality therapy
Number of subjects: 266
Study: 33636042

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (DE)
Number of subjects: 358
Study: 34202578

Group type: EXPERIMENTAL
Intervention: 5000 IU oral vitamin D3
Number of subjects: 69

Group type: COMPARATOR
Intervention: 1000 IU oral vitamin D3 (standard control)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both groups (5000 IU and 1000 IU)
Number of subjects: 69
Study: 35239819

Group type: EXPERIMENTAL
Intervention: Medication reconciliation (MED)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment (CON)
Number of subjects: 100
Study: 32272969

Group type: EXPERIMENTAL
Intervention: Manual ablation with an open‐irrigated ablation catheter equipped with CF sensing (used in a virtual nonirrigated modus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual ablation with standard nonirrigated ablation catheters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual ablation with open‐irrigated ablation catheter equipped with CF sensing
Number of subjects: 0
Study: 35910820

Group type: EXPERIMENTAL
Intervention: High-dose oral ivermectin plus zinc sulfate for 3 days
Number of subjects: 113

Group type: COMPARATOR
Intervention: Hydroxychloroquine, darunavir/ritonavir, and zinc sulfate for 5 days
Number of subjects: 113
Study: 34087468

Group type: EXPERIMENTAL
Intervention: RB-mediated PDT
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CUR-mediated PDT
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nystatin therapy
Number of subjects: 45
Study: 33257257

Group type: EXPERIMENTAL
Intervention: Radiology technologists measuring leg length discrepancies
Number of subjects: 4
Study: 34078408

Group type: EXPERIMENTAL
Intervention: Planned early delivery between 34+0 and 36+6 weeks
Number of subjects: 326
Study: 34256988

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) plus specific exercises
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham taping plus specific exercises
Number of subjects: 42
Study: 35701062

Group type: EXPERIMENTAL
Intervention: Case management intervention (CM) including education and patient navigation for colorectal cancer screening.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: In-person counselling with an explanation of the screening process by psychiatric care providers.
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Case management intervention (CM) from the perspective of psychiatric care providers.
Number of subjects: 153
Study: 36748363

Group type: EXPERIMENTAL
Intervention: CT-P17 (40 mg/0.4 ml)
Number of subjects: 205

Group type: COMPARATOR
Intervention: EU-adalimumab (40 mg)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: CT-P17 and EU-adalimumab
Number of subjects: 205
Study: 33587043

Group type: EXPERIMENTAL
Intervention: Benzodiazepine derivatives
Number of subjects: 396225

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 396225
Study: 35072795

Group type: COMPARATOR
Intervention: Smokers
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Obese patients (BMI > 30)
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Overweight patients (BMI > 25)
Number of subjects: 3012

Group type: COMPARATOR
Intervention: Overweight smokers
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 3012

Group type: EXPERIMENTAL
Intervention: Survival analysis
Number of subjects: 3012
Study: 33855449

Group type: EXPERIMENTAL
Intervention: Fosfomycin (100 mg/kg IV q12h for 48h, then converted to oral therapy at the same dose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 61
Study: 33989086

Group type: EXPERIMENTAL
Intervention: Home medication review by community pharmacists (HMR-CP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 35054148

Group type: EXPERIMENTAL
Intervention: Naloxegol
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 34277800

Group type: EXPERIMENTAL
Intervention: Modified reverse sural neurofasciocutaneous flap with extended reconstruction range
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional reverse sural neurofasciocutaneous flap procedures
Number of subjects: 24
Study: 36216274

Group type: EXPERIMENTAL
Intervention: Daily Partial Breast Irradiation (PBI) - 35 Gy in 10 daily fractions, with a 9 Gy boost in 3 fractions for patients with close margins
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Daily Partial Breast Irradiation (PBI)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Whole Breast Irradiation (WBI) + boost
Number of subjects: 149
Study: 32957859

Group type: EXPERIMENTAL
Intervention: GET FIT DON'T QUIT intervention
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 32700191

Group type: EXPERIMENTAL
Intervention: Single intravenous infusions of felbinac trometamol (11.78–377.00 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Multiple intravenous infusions of felbinac trometamol (47.13–188.50 mg)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Felbinac trometamol (various doses)
Number of subjects: 92
Study: 35762432

Group type: EXPERIMENTAL
Intervention: Nomogram model for predicting the risk of death during hospitalization
Number of subjects: 1714
Study: 33611240

Group type: EXPERIMENTAL
Intervention: Framingham 2008 risk score
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: SCORE (low and high-risk populations)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: ATP III risk score
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: World Health Organization-American B region (WHO-B)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Pooled Cohort equations (PC)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Non-fatal cardiovascular events (CVE)
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Non-cardiovascular deaths
Number of subjects: 606

Group type: EXPERIMENTAL
Intervention: Cardiovascular deaths
Number of subjects: 606
Study: 34081484

Group type: EXPERIMENTAL
Intervention: Delay Smoking Task (n = 39)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Posture Task (n = 36)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both task groups
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Delay Smoking Task
Number of subjects: 75
Study: 34654364

Group type: EXPERIMENTAL
Intervention: Video-based instruction
Number of subjects: 72

Group type: COMPARATOR
Intervention: Conventional lecture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Neonatal ward clinicians
Number of subjects: 72
Study: 35500171

Group type: EXPERIMENTAL
Intervention: Aspirin with PPIs
Number of subjects: 15839

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 15839

Group type: COMPARATOR
Intervention: Aspirin without PPIs
Number of subjects: 15839
Study: 34214585

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg tablets once daily for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo tablets once daily for 12 weeks
Number of subjects: 52
Study: 36345889

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pilates
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (asymptomatic participants)
Number of subjects: 24
Study: 34416879

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg daily for six months)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 33028425

Group type: EXPERIMENTAL
Intervention: Targeted hypothermia with a target temperature of 33 °C
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Targeted normothermia and active treatment of fever (≥ 37.8 °C)
Number of subjects: 1900
Study: 35858836

Group type: EXPERIMENTAL
Intervention: Hypoxia (12% O2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxia (21% O2)
Number of subjects: 8
Study: 34622702

Group type: EXPERIMENTAL
Intervention: High anticipated regret
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Favorable attitudes toward consequences of screening
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Concerns about pain
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Concerns about invasion of privacy
Number of subjects: 340
Study: 35659580

Group type: EXPERIMENTAL
Intervention: Erlotinib plus bevacizumab
Number of subjects: 160

Group type: COMPARATOR
Intervention: Erlotinib alone
Number of subjects: 160
Study: 32544609

Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 21

Group type: COMPARATOR
Intervention: FMISO-PET
Number of subjects: 21
Study: 36059956

Group type: EXPERIMENTAL
Intervention: Prophylactic TXA (10 mg/kg followed by 5 mg/kg/h) with TEG‐guided hemostatic algorithm
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conventional coagulation management
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Prophylactic TXA with TEG‐guided hemostatic algorithm
Number of subjects: 83
Study: 32817692

Group type: EXPERIMENTAL
Intervention: Tsima intervention (HIV treatment as prevention)
Number of subjects: 1189

Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 1189
Study: 36046991

Group type: EXPERIMENTAL
Intervention: Low-Intensity Interval Training (LIIT)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (CNT)
Number of subjects: 36
Study: 35864547

Group type: EXPERIMENTAL
Intervention: HOGO bed (intervention group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo group (control group)
Number of subjects: 18
Study: 33534905

Group type: EXPERIMENTAL
Intervention: Cellular Matrix (a mixture of a-PRP and HA)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Autologous Platelet-Rich Plasma (a-PRP)
Number of subjects: 93
Study: 32060155

Group type: EXPERIMENTAL
Intervention: Dexamethasone-based elixir mouthwash (10 mL 0.1 mg/mL; swish for 2 min and spit, four times daily for 9 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard oral care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone-based elixir mouthwash
Number of subjects: 120
Study: 34654569

Group type: EXPERIMENTAL
Intervention: Slush Nitrogen (SN)
Number of subjects: 556

Group type: COMPARATOR
Intervention: Liquid Nitrogen (LN)
Number of subjects: 556
Study: 36506010

Group type: EXPERIMENTAL
Intervention: SbV + NAC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NAC treatment of SLA-stimulated PBMCs
Number of subjects: 60

Group type: COMPARATOR
Intervention: SbV
Number of subjects: 60
Study: 32474302

Group type: EXPERIMENTAL
Intervention: Intensive lipid-lowering therapy (pitavastatin + ezetimibe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional lipid-lowering therapy (pitavastatin monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Group 3, HDL-C ≥53.6 mg/dL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Overall comparison of Groups 1 and 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin + ezetimibe therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pitavastatin monotherapy
Number of subjects: 0
Study: 35238491

Group type: EXPERIMENTAL
Intervention: Low-amplitude WBV (LO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-amplitude WBV (HI)
Number of subjects: 40
Study: 33554032

Group type: EXPERIMENTAL
Intervention: Modified TNM (mTNM) classification
Number of subjects: 45379

Group type: COMPARATOR
Intervention: AJCC 8th TNM classification
Number of subjects: 45379
Study: 33339359

Group type: EXPERIMENTAL
Intervention: Caffeine-containing energy shot (CAF, 5 mg/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Decaffeinated energy shot (DECAF)
Number of subjects: 20
Study: 35986400

Group type: EXPERIMENTAL
Intervention: Clean Cut intervention (modifying and implementing the WHO Surgical Safety Checklist, process mapping, site-specific action plans, targeted training)
Number of subjects: 8100

Group type: EXPERIMENTAL
Intervention: Clean Cut intervention
Number of subjects: 8100
Study: 34860351

Group type: EXPERIMENTAL
Intervention: Vitamin D combined with clomiphene citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32721973

Group type: EXPERIMENTAL
Intervention: Early spot urinary sodium (UNa)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Diuretic efficiency
Number of subjects: 160
Study: 36433919

Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment (target 110 to <130 mmHg)
Number of subjects: 3989

Group type: COMPARATOR
Intervention: Standard SBP treatment (target 130 to <150 mmHg)
Number of subjects: 3989

Group type: EXPERIMENTAL
Intervention: Intensive SBP treatment
Number of subjects: 3989

Group type: COMPARATOR
Intervention: Standard SBP treatment
Number of subjects: 3989
Study: 33225631

Group type: EXPERIMENTAL
Intervention: Anifrolumab 1000 mg IV every 4 weeks, reduced to 300 mg every 4 weeks based on benefit/risk profile
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Anifrolumab
Number of subjects: 246
Study: 32768393

Group type: EXPERIMENTAL
Intervention: Osilodrostat
Number of subjects: 66
Study: 36184780

Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dulaglutide 0.75 mg
Number of subjects: 48
Study: 33961176

Group type: EXPERIMENTAL
Intervention: FIND intervention group
Number of subjects: 91

Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 91
Study: 35182101

Group type: EXPERIMENTAL
Intervention: Lean pork (156 g day-1)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chicken (active-control, 156 g day-1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lean pork
Number of subjects: 36

Group type: COMPARATOR
Intervention: Chicken
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lean pork and Chicken
Number of subjects: 36
Study: 33793146

Group type: EXPERIMENTAL
Intervention: Khār-i-khasak (Tribulus terrestris Linn.)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 36086767

Group type: EXPERIMENTAL
Intervention: AP‐IMRT with MSA of 4-50 cm2
Number of subjects: 10
Study: 32816215

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg twice daily (b.d.) induction therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg b.d. maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib Overall cohort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib-treated patients with rheumatoid arthritis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib-treated patients with psoriasis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tofacitinib-treated patients with psoriatic arthritis
Number of subjects: 0
Study: 35781465

Group type: EXPERIMENTAL
Intervention: Addiction Comprehensive Health Enhancement Support System app
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone Monitoring and Counseling
Number of subjects: 0
Study: 35188552

Group type: EXPERIMENTAL
Intervention: Fluorouracil
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Carboplatin
Number of subjects: 321
Study: 34485096

Group type: EXPERIMENTAL
Intervention: Op Koers Online (N = 35)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Waitlist control group (N = 24)
Number of subjects: 59
Study: 34910595

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.5 mg/kg, twice daily for 2 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 32049283

Group type: EXPERIMENTAL
Intervention: Self-expandable valve (SEV) - Evolut R, Medtronic Inc.
Number of subjects: 447

Group type: COMPARATOR
Intervention: Balloon-expandable valve (BEV) - Sapien 3, Edwards Lifesciences
Number of subjects: 447